Novel Peri-Vascular Drug Delivery for the Treatment of Neointimal Hyperplasia Associated with Ptfe Dialysis Graft Failure

Intimal hyperplasia (IH), that leads to hemodialysis access dysfunction, is a major problem affecting patients undergoing renal dialysis. This work aimed at developing a novel approach that entails peri-vascular delivery of cytotoxic agents such as paclitaxel for the inhibition...

The Truth About the Drug Companies

During her two decades at The New England Journal of Medicine, Dr. Marcia Angell had a front-row seat on the appalling spectacle of the pharmaceutical industry. She watched drug companies stray from their original mission of discovering and manufacturing...

Drug Muggers

Unpleasant, uncomfortable, and unexplained side effects? Drug Muggers is your side effect solution. Prescription and over-the-counter drugs help millions of people with devastat-ing diseases and chronic conditions. But in the process, these medications can also deplete the body’s natural...

Food: The Good Girl’s Drug

Bingeing, compulsive eating, food addiction, emotional overeating—no matter what you call it, too many women wrestle day to day with what they eat. It’s a love-hate relationship that always seems to be spiraling out of control. Food: The Good...

Ximelagatran (Exanta): Alternative to Warfarin?(Pharmacology Notes) (Drug Overview)

For decades, the standards of antithrombotic therapy have been heparin and coumarin compounds, primarily warfarin (1). Other newer approaches include low-molecular-weight heparins, fondaparinux, lepirudin, argatroban, and melagatran (investigational). Although existing treatments are effective, they have many limitations. A safer,...

Darbepoetin Alfa (Aranesp) (Pharmacology Notes) (Drug Overview)

The Food and Drug Administration (FDA) approved darbepoetin alfa (Aranesp) for treatment of anemia as sociated with chronic renal failure (CRF) in patients on dialysis and patients not on dialysis (1). The manufacturer of the drug also filed an...

Emergence of Extensive Drug Resistance (XDR) Among Gramnegative Bacilli in South Africa Looms Nearer (Issues IN PUBLIC Health) (Report)

Until recently, the term ‘extensive drug resistance’ (XDR) was held to be applicable to Mycobacterium tuberculosis only. It is now clear that Gram-negative bacilli are moving a step closer towards acquiring similar resistance. The emergence of multi(MDR) and pan-drug...

Surprises of Off-Label Drug Use–Where had All the Prostin Gone? (Issues in Medicine)

The off-label use of drugs is common, particularly in paediatrics, where many drugs have yet to undergo the rigorous scrutiny demanded by authorities such as the Medicines Control Council (MCC) and the US Food and Drug Administration (FDA) before...

2008 New Drug Approvals (Pharmacology Notes) (Drug Overview)

This article provides a brief review of selected new drug entities approved by the Food and Drug Administration (FDA) in 2008. ALVIMOPAN (ENTEREG)

Effect of Efflux Pump Inhibitors on Drug Susceptibility of Ofloxacin Resistant Mycobacterium Tuberculosis Isolates (Report)

Mycobacterium tuberculosis, the aetiological agent of tuberculosis (TB), has re-emerged as a killer pathogen in western countries after the increase of HIV-AIDS cases and development of resistance to various anti-tubercular drugs. This increase in the number of multi-drug resistant...

Pkdl–a Drug Related Phenomenon? (Commentary) (Post-Kala-Azar Dermal Leishmaniasis ) (Clinical Report)

Post-kala-azar dermal leishmaniasis (PKDL) is a cutaneous manifestation of visceral leishmaniasis (VL), characterized by skin lesions, nodules or papules, frequently on the face. It often appears 2-7 years after the apparently successful treatment of VL by antimonial drugs. It...

Bacterial Pathogens and Their Drug Sensitivity Pattern in Acute Otitis Media in Children at Children Hospital Chandka Medical College Larkana (Report)

Byline: Arbab Ali Junejo, Khurshid Ahmed Abbasi, Haresh Chand and Raja Rahul Chand ABSTRACT

Eszopiclone (Lunesta): A New Nonbenzodiazepine Hypnotic Agent (Pharmacology Notes) (Drug Overview)

Randomized, placebo-controlled trials have shown that eszopiclone, a newly available nonbenzodiazepine hypnotic, effectively treats the symptoms of insomnia. Its pharmacokinetic and pharmacodynamic parameters are similar to those of the other currently available nonbenzodiazepine hypnotics (i.e., zolpidem and zaleplon). The...

Human Subject Protection – Acceptance of Data From Clinical Investigations for Medical Devices (US Food and Drug Administration Regulation) (FDA) (2018 Edition)

The Law Library presents the complete text of the Human Subject Protection – Acceptance of Data From Clinical Investigations for Medical Devices (US Food and Drug Administration Regulation) (FDA) (2018 Edition).Updated as of May 29, 2018 The Food and...

Preemption, Tort Reform, And Pharmaceutical Claims: Part Two: Has the Food and Drug Administration Shown It is Solely Responsible for the Protection of Patients? can It Do So? will It Do So?(Medicolegal Issues)

There should be no question that adverse drug events are a significant issue. A recent report indicated that in 2005 there were 89,842 serious adverse drug-related events (1), and 15,107 of these adverse events were deaths (1). In 2002,...

Tiotropium (Spiriva): A Once-Daily Inhaled Anticholinergic Medication for Chronic Obstructive Pulmonary Disease (Pharmacology Notes) (Drug Overview)

Tiotropium represents a new generation of inhaled therapy. No other inhaled product has demonstrated effectiveness with once-daily dosing. Treatment has been associated with improved lung function, decrease in the number of exacerbations, increase in the time to first exacerbation,...

Palonosetron (Aloxi): A Second-Generation 5-H[T.Sub.3] Receptor Antagonist for Chemotherapy-Induced Nausea and Vomiting (Pharmacology Notes) (Drug Overview)

In July 2003, the Food and Drug Administration approved palonosetron hydrochloride injection for the treatment of chemotherapy-induced nausea and vomiting (CINV). The newest agent in the class of 5-H receptor antagonists (5-HRAs), palonosetron differs from other agents in its...

Fluoroquinolone Drug Class Update (Pharmacology Notes)

The approval of trovafloxacin (Trovan, Pfizer Pharmaceuticals, New York, NY) by the Food and Drug Administration (FDA) in 1998 was met with great excitement by many clinicians based on its utility as monotherapy for numerous indications. In comparison with...

Medicare Modernization: The New Prescription Drug Benefit and Redesigned Part B and Part C.

The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 was enacted in November 2003 and became effective on January 1, 2006. Two major changes occurred. A prescription drug benefit is now available for seniors and younger persons with...

Drotrecogin Alfa (Activated): The First Fda-Approved Treatment for Severe Sepsis (Pharmacology Notes) (Drug Overview)

Drotrecogin alfa (activated) (Xigris, Eli Lilly and Company, Indianapolis, Ind) is a recombinant form of human activated protein C. It was approved by the Food and Drug Administration in the last quarter of 2001 for the reduction of mortality...